Published in Philos Trans R Soc Lond B Biol Sci on January 05, 2018
Extracellular vesicles in the tumour microenvironment. Philos Trans R Soc Lond B Biol Sci (2018) 0.75
Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol (2013) 10.02
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles (2014) 3.86
The hematopoietic stem cell in its place. Nat Immunol (2006) 3.70
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34
Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene (2012) 2.01
Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood (2014) 2.00
Communication by Extracellular Vesicles: Where We Are and Where We Need to Go. Cell (2016) 1.93
Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 1.87
Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol (2014) 1.71
Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood (2015) 1.70
Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. Angiogenesis (2011) 1.53
Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J Biol Chem (2013) 1.40
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia (2011) 1.39
Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica (2011) 1.37
Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis. Int J Cancer (2011) 1.34
The biology and function of fibroblasts in cancer. Nat Rev Cancer (2016) 1.16
Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica (2005) 1.14
Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood (2014) 1.13
Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an interleukin 8-dependent survival of leukemia cells. Cancer Lett (2014) 1.09
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood (2015) 1.04
Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells. Mol Cancer (2014) 1.01
Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism. Cell Commun Signal (2015) 0.97
Serum Exosome MicroRNA as a Minimally-Invasive Early Biomarker of AML. Sci Rep (2015) 0.95
Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev (2016) 0.91
Microvesicles secreted from human multiple myeloma cells promote angiogenesis. Acta Pharmacol Sin (2013) 0.89
Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study. Leukemia (2003) 0.89
Characterization of multiple myeloma vesicles by label-free relative quantitation. Proteomics (2013) 0.89
The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget (2015) 0.85
Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget (2014) 0.84
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation. Oncotarget (2015) 0.83
CLL Exosomes Modulate the Transcriptome and Behaviour of Recipient Stromal Cells and Are Selectively Enriched in miR-202-3p. PLoS One (2015) 0.80
Cancer associated fibroblasts in hematological malignancies. Oncotarget (2015) 0.79
Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer (2014) 0.79
AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Sci Signal (2016) 0.78
Acute lymphoblastic leukaemia cells produce large extracellular vesicles containing organelles and an active cytoskeleton. J Extracell Vesicles (2017) 0.78
Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. J Pathol (2016) 0.78
Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. Leukemia (2015) 0.78
Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. Cancer Lett (2016) 0.78
In Brief: Myeloid-derived suppressor cells in cancer. J Pathol (2017) 0.77
Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood (2017) 0.77
The emerging roles of exosomes in leukemogeneis. Oncotarget (2016) 0.76
Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance. Br J Haematol (2015) 0.75
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study. Am J Hematol (2015) 0.77
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget (2015) 0.76
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells. Oncotarget (2016) 0.75
Unique radiological features of two cases of primary pulmonary diffuse large B-cell lymphoma. Thorax (2017) 0.75
A phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome. Cancer Sci (2017) 0.75
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. Oncol Rep (2016) 0.75